<DOC>
	<DOC>NCT00373516</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of two dosing regimens of QRX-101 ointment (75 mcg/g QD and 75mcg/g BID) in the treatment of plaque-type psoriasis when applied topically twice daily for 8 weeks</brief_summary>
	<brief_title>Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Clinical diagnosis of stable plaquetype psoriasis affecting 2% to 10% of the subjectâ€™s body surface area Psoriasis of a severity that is appropriate for treatment with topical therapy; PGA of at least 3 (moderate) at baseline; PSS of at least 7, and with no individual symptom score (erythema, induration, or scaling) less than 2 Subject must sign the IRB approved informed consent and agree to follow dosing instructions and complete required clinic visits. Pregnant or nursing females Systemic corticosteroids, methotrexate, cyclosporine, systemic retinoids, prolonged sun exposure or ultraviolet light therapy within 4 weeks of dosing Topical corticosteroids, retinoids, calcipotriene, coal tar, anthralin, or any other treatment indicated for psoriasis within 2 weeks of dosing Untreated bacterial, tubercular, fungal or any viral lesion of the skin Biologic agents/monoclonal antibodies in the last 6 months Currently using lithium or plaquenil Currently using a betablocking medication or thiazide diuretic and the dose has not been stabilized for at least 6 months History of hypercalcemia or evidence of vitamin D toxicity Current or history of melanoma skin cancer in the past 5 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>topical therapy</keyword>
</DOC>